A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT by Cheadle, J, Smith, C, Fisher, D, Maughan, T, Moskvina, V, Meade, A, West, H, Kaplan, R

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB by Smith, C, Claes, B, Fisher, D, Adams, R, Kaplan, R, Meade, A, Lambrechts, D, Maughan, T, Cheadle, J

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED by Maughan, T, Wilson, R, Seymour, M, Meade, A, Fisher, D, Kenny, S, Smith, C, Cheadle, J, Kaplan, R, Adams, R

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBS... by Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, Kaplan, R

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN... by Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, Kaplan, R

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials by Seligmann, JF, Fisher, D, Smith, CG, Richman, SD, Elliott, F, Brown, S, Adams, R, Maughan, T, Quirke, P, Cheadle, J, Seymour, M, Middleton, G

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy by West, H, Coffey, M, Wagner, M, McLeod, H, Colley, J, Adams, R, Fleck, O, Maughan, T, Fisher, D, Kaplan, R, Harris, R, Cheadle, J

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy by Madi, A, Fisher, D, Maughan, T, Colley, J, Meade, A, Maynard, J, Humphreys, V, Wasan, H, Adams, R, Idziaszczyk, S, Harris, R, Kaplan, R, Cheadle, J

A novel colorectal cancer susceptibility SNP in the EIF3F1 promoter influences patient survival and response to treatment by Smith, C, Smith, C, Fisher, D, Harris, R, Maughan, T, Idziaszczyk, S, Moskvina, V, Colley, J, Meade, A, Bonnet, C, West, H, Kaplan, R, Cheadle, J

Response. by Smith, C, West, H, Harris, R, Idziaszczyk, S, Maughan, T, Kaplan, R, Richman, S, Quirke, P, Seymour, M, Moskvina, V, Steinke, V, Propping, P, Hes, F, Wijnen, J, Cheadle, J

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. by Smith, C, Fisher, D, Claes, B, Maughan, T, Idziaszczyk, S, Peuteman, G, Harris, R, James, MD, Meade, A, Jasani, B, Adams, R, Kenny, S, Kaplan, R, Lambrechts, D, Cheadle, J

Exome Resequencing Identifies Potential Tumor-Suppressor Genes that Predispose to Colorectal Cancer by Smith, C, Naven, M, Harris, R, Colley, J, West, H, Li, N, Liu, Y, Adams, R, Maughan, T, Nichols, L, Kaplan, R, Wagner, M, Mcleod, H, Cheadle, J

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. by Smith, C, West, H, Harris, R, Idziaszczyk, S, Maughan, T, Kaplan, R, Richman, S, Quirke, P, Seymour, M, Moskvina, V, Steinke, V, Propping, P, Hes, F, Wijnen, J, Cheadle, J

Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. by Smith, C, Naven, M, Harris, R, Colley, J, West, H, Li, N, Liu, Y, Adams, R, Maughan, T, Nichols, L, Kaplan, R, Wagner, M, McLeod, H, Cheadle, J

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (... by Adams, R, Maughan, T, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Kenny, S, Wasan, H, Rogers, P, Hodgkinson, E, Jasani, B, Cheadle, J, Kaplan, R

Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. by Lamlum, H, Al Tassan, N, Jaeger, E, Frayling, I, Sieber, O, Reza, F, Eckert, M, Rowan, A, Barclay, E, Atkin, W, Williams, C, Gilbert, J, Cheadle, J, Bell, J, Houlston, R, Bodmer, W, Sampson, J, Tomlinson, I

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. by Maughan, T, Adams, R, Smith, C, Meade, A, Seymour, M, Wilson, R, Idziaszczyk, S, Harris, R, Fisher, D, Kenny, S, Kay, E, Mitchell, J, Madi, A, Jasani, B, James, MD, Bridgewater, J, Kennedy, M, Claes, B, Lambrechts, D, Kaplan, R, Cheadle, J

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer by Gray, V, Briggs, S, Palles, C, Jaeger, E, Iveson, T, Kerr, R, Saunders, M, Paul, J, Harkin, A, McQueen, J, Summers, M, Johnstone, E, Wang, H, Gatcombe, L, Maughan, T, Kaplan, R, Escott-Price, V, Al-Tassan, N, Meyer, B, Wakil, S, Houlston, R, Cheadle, J, Tomlinson, I, Church, D

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. by Houlston, R, Cheadle, J, Dobbins, SE, Tenesa, A, Jones, A, Howarth, K, Spain, S, Broderick, P, Domingo, E, Farrington, S, Prendergast, J, Pittman, A, Theodoratou, E, Smith, C, Olver, B, Walther, A, Barnetson, R, Churchman, M, Jaeger, E, Penegar, S, Barclay, E, Martin, L, Gorman, M, Mager, R, Johnstone, E

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33 by Houlston, R, Cheadle, J, Dobbins, SE, Tenesa, A, Jones, A, Howarth, K, Spain, S, Broderick, P, Domingo, E, Farrington, S, Prendergast, J, Pittman, A, Theodoratou, E, Smith, C, Olver, B, Walther, A, Barnetson, R, Churchman, M, Jaeger, E, Penegar, S, Barclay, E, Martin, L, Gorman, M, Mager, R, Johnstone, E